TriSalus Life Sciences
TLSI
53 hedge funds and large institutions have $139M invested in TriSalus Life Sciences in 2021 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 15 increasing their positions, 3 reducing their positions, and 3 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 3
333% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 3
20% more funds holding
Funds holding: 44 → 53 (+9)
11% more capital invested
Capital invested by funds: $125M → $139M (+$13.6M)
5.85% more ownership
Funds ownership: 51.77% → 57.62% (+5.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VI
Vestcor Inc
Fredericton,
New Brunswick, Canada
|
+$2.29M |
| 2 |
PMAM
Picton Mahoney Asset Management
Toronto,
Ontario, Canada
|
+$2.21M |
| 3 |
MA
MYDA Advisors
Woodmere,
New York
|
+$1.96M |
| 4 |
JGC
J. Goldman & Co
New York
|
+$1.83M |
| 5 |
SV
Starboard Value
New York
|
+$1.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.37M |
| 2 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$966K |
| 3 |
WRBC
W.R. Berkley Corp
Greenwich,
Connecticut
|
-$240K |
| 4 |
Morgan Stanley
New York
|
-$1.23K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
JP Morgan Chase
New York
| $2K | +$2.06K | +210 | New |
|
|
KJHP
52
K.J. Harrison & Partners
Toronto,
Ontario, Canada
| $1.36K | – | – | – |
|
|
53
Morgan Stanley
New York
| $1K | -$1.23K | -125 | -56% |
|
|
MP
54
Mangrove Partners
Greenwich,
Connecticut
| – | -$966K | -100,000 | Closed |
|
|
WRBC
55
W.R. Berkley Corp
Greenwich,
Connecticut
| – | -$240K | -24,846 | Closed |
|
|
TRCT
56
Tower Research Capital (TRC)
New York
| – | -$1K | -100 | Closed |
|
TLSI Hedge Fund Activity: Q2 2021 in Review
53 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in TriSalus Life Sciences (TLSI) for Q2 2021, worth a combined $139M — up 11% from $125M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new TLSI positions and 3 closed out — a net gain of 10 holders — while 15 added to existing stakes and 3 trimmed.
The largest buyer was Vestcor Inc, adding an estimated $2.29M. The largest seller was Wellington Management Group, cutting an estimated $1.37M.
- 53 institutional investors held TriSalus Life Sciences (TLSI) as of Q2 2021, up from 44 in Q1 2021.
- Funds reported $139M of TriSalus Life Sciences stock for Q2 2021, up 11% quarter-over-quarter.
- 13 funds opened new TriSalus Life Sciences positions in Q2 2021 and 3 closed out, a net change of +10 holders.
- The largest TriSalus Life Sciences buyer in Q2 2021 was Vestcor Inc, an estimated $2.29M added.
- The largest TriSalus Life Sciences seller in Q2 2021 was Wellington Management Group, an estimated $1.37M sold.
Based on aggregated 13F filings for Q2 2021.